- Home
- LIXT vs AEI Comparison
LIXT vs AEI Comparison
Compare LIXT & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- AEI
- Stock Information
- Founded
- LIXT 2005
- AEI 2014
- Country
- LIXT United States
- AEI United States
- Employees
- LIXT N/A
- AEI N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- AEI Building operators
- Sector
- LIXT Health Care
- AEI Real Estate
- Exchange
- LIXT Nasdaq
- AEI Nasdaq
- Market Cap
- LIXT 12.4M
- AEI 13.6M
- IPO Year
- LIXT N/A
- AEI N/A
- Fundamental
- Price
- LIXT $4.85
- AEI $1.16
- Analyst Decision
- LIXT
- AEI
- Analyst Count
- LIXT 0
- AEI 0
- Target Price
- LIXT N/A
- AEI N/A
- AVG Volume (30 Days)
- LIXT 193.9K
- AEI 85.6K
- Earning Date
- LIXT 08-07-2025
- AEI 08-19-2025
- Dividend Yield
- LIXT N/A
- AEI N/A
- EPS Growth
- LIXT N/A
- AEI N/A
- EPS
- LIXT N/A
- AEI N/A
- Revenue
- LIXT N/A
- AEI $16,097,995.00
- Revenue This Year
- LIXT N/A
- AEI N/A
- Revenue Next Year
- LIXT N/A
- AEI N/A
- P/E Ratio
- LIXT N/A
- AEI N/A
- Revenue Growth
- LIXT N/A
- AEI N/A
- 52 Week Low
- LIXT $0.64
- AEI $0.70
- 52 Week High
- LIXT $5.14
- AEI $2.61
- Technical
- Relative Strength Index (RSI)
- LIXT 64.92
- AEI 47.54
- Support Level
- LIXT $4.20
- AEI $1.13
- Resistance Level
- LIXT $5.06
- AEI $1.23
- Average True Range (ATR)
- LIXT 0.44
- AEI 0.11
- MACD
- LIXT -0.02
- AEI -0.03
- Stochastic Oscillator
- LIXT 80.79
- AEI 7.07
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.